Canton, MA, July 29, 2019 - Abveris, Inc., a leader in contract research antibody discovery, today announced that it has entered into a collaborative agreement with Lava Therapeutics BV, a biopharmaceutical company developing next-generation T cell engager therapies. Under the terms of the agreement, Abveris will leverage its proprietary technology to develop critical reagent antibodies to support assay development for bispecific antibody γδ T cell engagers selected by Lava Therapeutics.
“The Abveris team is pleased to be working with Lava to accelerate the path to clinical development for their lead compound,” commented Ryan Kelly, Director of Business Development at Abveris. “We apply our proprietary hyperimmune platform to deliver consistent results for diverse biotherapeutic molecule formats. We look forward to working with the Lava Therapeutics team to help advance their γδ T cell engaging bispecific molecules.”
“We are delighted to enter a collaboration with Abveris on the generation of high-quality antibodies as critical reagents in our drug development programs of bispecific γδ T cell engagers. The use of the Abveris hyperimmune platform will enable the accelerated development of advanced (non-)clinical assays for our programs.” said Ton Adang, Senior VP and CDO of Lava Therapeutics B.V.
Abveris is a premium Boston-area contract research organization specializing in antibody discovery. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at www.abveris.com.
About Lava Therapeutics:
Lava Therapeutics’ proprietary platform is focused on developing next-generation γδ T cell engaging bispecific antibodies to treat cancer. Lava’s vision is to develop therapeutics for the curative treatment of cancer. For more information, please visit www.lavatherapeutics.com.
Contact for Abveris:
Contact for Lava Therapeutics: